Cervical Cancer Prevention Week 2018
Cervical Cancer Prevention Week 2018 will take place between Monday 22nd January and Sunday 28th January. The event runs annually to raise awareness and funds for research. The theme for Cervical Cancer Prevention Week 2018 is “Reduce your risk”.
Cervical cancer can be prevented but almost half a million young women aged 25-29 did not attend cervical screening last year. Cervical Cancer Prevention Week aims to change this.
- Attending cervical screening when invited
- Knowing the symptoms of cervical cancer and seeking medical advice if experiencing any
- Taking up the HPV vaccination if aged 11-18
- Talking to friends and family to ensure they know how they can reduce their risk
- Knowing where to find support and further information
Jo’s Cervical Cancer Trust is calling on the public to help them raise awareness of cervical screening by getting involved with their #SmearForSmear campaign.
About Cervical Cancer:
According to the European Society for Medical Oncology, cervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries.
- Every day in the UK 9 women are diagnosed with cervical cancer
- Around 2 women lose their lives from the disease every day
- Cervical cancer is the most common cancer in women under 35
- 75% of cervical cancers can be prevented by cervical screening (smear tests)
- However, 1 in 4 women do not attend this potentially life-saving test
Related news and insights
Merck Inc., known as MSD outside of the United States and Canada, announced results from the pivotal Phase III KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating Keytruda Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy (EBRT) plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) for newly diagnosed patients with high-risk locally advanced cervical cancer (stage 1B2-2B with lymph node-positive disease, and stage 3-4A with and without lymph node-positive disease).
Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for Keytruda, Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy (EBRT) plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) as treatment with definitive intent for newly diagnosed patients with high-risk locally advanced cervical cancer.
Seagen Inc. and Genmab A/S announced that the Phase III innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS)